Review Article

Moxibustion for Diarrhea-Predominant Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Bozong Tang, Jianliang Zhang, Zongguo Yang, Yunfei Lu, Qingnian Xu, Xiaorong Chen, and Jiang Lin

1. Introduction

Irritable bowel syndrome (IBS) is a chronic, recurrent functional gastrointestinal (GI) disorder characterized by altered bowel habits and abdominal pain or discomfort [1]. The prevalence of IBS ranges from 5% to 20% in the general population worldwide [2]. The high prevalence of IBS results in a substantial socioeconomic burden through decreased work productivity and quality of life and increased direct and indirect healthcare costs [3–5]. The direct and indirect healthcare costs related to IBS in the United States have been steadily increasing and amounted to 1.35 billion dollars in 2003 [6]. The worldwide health costs associated with IBS are estimated to exceed 200 billion dollars [7].

The etiology and pathophysiology of IBS remain less understood. Abnormal intestinal motility, visceral hypersensitivity, abnormal neurohormonal responses to stimuli or stress, and alteration of normal intestinal microflora are related to IBS [1]. The available western medications mainly target symptom relief, such as antispasmodics, fiber supplementation, and antidepressants. Due to limited therapeutic efficacy and the side effects of western medications, up to 51% of IBS patients, especially IBS-D patients, are interested in complementary and alternative medicine (CAM) [8, 9]. Moxibustion is a type of CAM approach that stimulates specific points to improve general health and treat chronic conditions with heat generated by burning dried mugwort (Artemisia vulgaris) leaves [10].
The average incidence of diarrhea-predominant IBS (IBS-D) is quite high and is showing an increasing trend; it seriously impacts the life quality of patients [11]. In CAM practice, most IBS-D patients have a deficiency of both the spleen and stomach, insufficiency of the kidney yang, and incoordination between the liver and the spleen which are suitable for moxibustion therapy [12]. Although a meta-analysis showed that moxibustion can improve global symptoms of IBS, no systematic study has evaluated the effectiveness of moxibustion treatment for IBS-D [13]. Moreover, some studies including acupuncture or pharmacological medications may influence results [14, 15].

Therefore, we conducted a systematic review and meta-analysis to evaluate all the currently available randomized controlled trials (RCTs) of moxibustion compared with pharmacological medications for symptom improvement in IBS-D patients.

2. Materials and Methods

2.1. Search Strategy. We searched the following electronic databases through March 2015: PubMed, Ovid Embase, Web of Science, and Cochrane Library databases, Chinese National Knowledge Infrastructure (CNKI) Database, Wanfang Database, Chinese Biomedical (CBM) Database, Chinese Science and Technology Periodical Database (VIP), and Allied and Complementary Medicine Database (AMED). We used a combination of medical subject headings without language limitation: irritable bowel syndrome (IBS), diarrhea, diarrhea-predominant irritable bowel syndrome, moxibustion, moxibustion therapy, moxa-moxibustion, warm-moxibustion, complementary therapies, Chinese medicine, traditional medicine, alternative medicine, complementary medicine, randomized controlled trial, and controlled clinical trial. Reference lists from trials selected by electronic searching and conference compilations were manually searched. The literature search was conducted by Bozong Tang and Zongguo Yang independently.

2.2. Study Selection. Two authors independently selected trials and discussed inconsistencies. Articles that met the following criteria were included: (1) randomized controlled trials; (2) patients with chronic IBS-D; (3) intervention that was moxibustion compared with western medications; (4) studies that measured improvement of symptoms or scores; and (5) available full text. Studies that included other treatments influencing the curative effect of moxibustion, including acupuncture and electroacupuncture, were excluded.

2.3. Data Extraction and Quality Assessment. Two reviewers screened all the retrieved trials independently and extracted the following content: publication data, study design, sample size, subject characteristics, treatment protocol, and outcome measurement. The methodological qualities of all the eligible RCTs were assessed independently by two reviewers according to Cochrane Collaboration’s tool described in Handbook version 5.1.0 [22]. Two authors (Bozong Tang and Zongguo Yang) assessed the quality independently; and inconsistency was discussed with a third review author (Jiang Lin) who acted as an arbiter.

2.4. Statistical Methods. Data were processed in accordance with the Cochrane Handbook [22]. Intervention effects were presented with odds ratios (ORs) and 95% confidence intervals (CIs) for dichotomous data and mean differences (MDs) and 95% CIs for continuous data. Continuous data of subgroups of each study were pooled using the following formula [23]:

\[
SD = \sqrt{\frac{(N_1 - 1) SD_1^2 + (N_2 - 1) SD_2^2 + (N_1 N_2 / (N_1 + N_2)) (M_1^2 + M_2^2 - 2M_1 M_2)}{N_1 + N_2 - 1}},
\]

where SDs were the standard deviations, Ns were the sample sizes, and Ms were the means.

Heterogeneity across studies was informally assessed by visual inspection of forest plots and formally estimated by Cochran’s Q test, which uses a chi-square distribution to make inferences about the null hypothesis of homogeneity (considered significant at \( P < 0.10 \)). A rough guide to our interpretation of \( I^2 \) was as follows:

(i) At 0–40%, it may not be important.
(ii) At 30–60%, it may represent moderate heterogeneity.
(iii) At 50–90%, it may represent substantial heterogeneity.
(iv) At 75–100%, it reflects considerable heterogeneity [22, 24].

If the eligibility of any study in the meta-analysis was dubious because of incomplete data, a sensitivity analysis was performed. If there was no heterogeneity among the trials, a fixed effects model would be applied in a meta-analysis. If there was heterogeneity among the trials, a random-effects model would be used instead in the meta-analysis. A description analysis was performed if the quantitative data could not be pooled. Review Manage (RevMan) version 5.3 software was used for data analysis.

3. Results

3.1. Study and Patient Characteristics. After primarily searching in 7 databases, 165 papers were found. However, 144 papers were excluded due to ineligibility after reviewing the titles and the abstracts. Additional 14 papers were excluded...
due to duplication and unavailable information on participants, interventions, and outcomes. Finally, 7 randomized controlled trials [12, 16–21] were included in this review: 3 trials published in English journals and 4 trials published in Chinese journals (Figure 1). A total of 568 patients were randomly treated with moxibustion or a pharmacological medication. The baseline characteristics of patients included in this meta-analysis are described in Table 1.

3.2. Methodological Quality Assessment. All studies included in this meta-analysis were randomized controlled trials. Four studies [12, 16–18] did not report the method of randomization, whereas the other three reported a randomization number sequence or adaptive minimization randomization scheme [19–21]. Except for Ma et al’s study using the single blind method, all the other studies did not adopt a blind method. These studies had high performance bias and detection bias. Selective reporting was found in Chen and Wang’s study [20] because it did not present the ITT analysis data. The other potential biases were unclear in these trials (Figure 2). Because all the studies were conducted in China and clinical outcomes of overall IBS-D symptoms and scores were subjective, we cautiously drew the conclusion that publication bias might have been present in this meta-analysis.

3.3. Overall IBS-D Symptoms or Scores. The efficacy of moxibustion treatment alone was compared with that of pharmacological medication treatment in 7 studies [12, 16–21]. Improvement of global IBS-D symptoms was reported in 4 studies [16, 17, 19, 20], and improvement of IBS-D scores was reported in the other 3 studies [17, 18, 21]. There was no significant heterogeneity among the included studies [16–21] \( (P = 0.97, I^2 = 0\%) \). A random-effect model was applied to compare the efficacy of moxibustion treatment and medication treatment. The effects of moxibustion on the improvement of the effective rate of overall IBS-D symptoms and the overall IBS-D symptoms scores were both superior to those of medication \( (P = 0.0002, \text{Figure } 3(a), \text{and } P = 0.0001, \text{Figure } 3(b)) \).

3.4. Specific IBS-D Symptoms. Improvement of specific IBS-D symptoms such as abdominal pain, abdominal distension, abnormal stool, and defecation frequency was reported in 2 studies [17, 19]. The heterogeneity of abdominal pain, abdominal distension, abnormal stool, and defecation frequency among the included studies was not significant before treatment \( (P = 0.69, P = 0.94, P = 0.78, \text{and } P = 0.54, \text{resp.}) \). However, the heterogeneity of the specific symptoms, except for defecation frequency, was significant after treatment. Thus, a random-effects model was
| Study year | Number of patients | Publishing language | Diagnostic criteria | Criteria for improvement in overall IBS-D symptoms | Time point for outcome assessment | Moxibustion treatment(s) | Control treatment(s) |
|------------|--------------------|---------------------|--------------------|---------------------------------------------|---------------------------------|------------------------|---------------------|
| Ni and Lu 2001 [12] | 56 | English | Negative GI investigations and standards for clinical diagnosis for IBS from 1986 National conference for chronic diarrhea | Change of total IBS symptom score (predefined) | 15 days (EoT) | Fixed points | Nifedipinum, 10 mg t.i.d. |
| Zhang et al. 2007 [16] | 60 | Chinese | Rome II | ≥30% improvement in global IBS symptoms | 2 weeks (EoT) | Ginger-partitioned and fixed points | Diet, psychiatric, and antidiarrheal therapy Enterosoluble glutamine 0.4 g t.i.d. or Smecta 3 g t.i.d. or probiotics 630 mg t.i.d. |
| Jin 2009 [17] | 78 | Chinese | Rome II | ≥30% improvement in global IBS symptoms | 30 days (EoT) | Traditional Chinese ointments-partitioned and fixed points | Berberine hydrochloride 2 tablets t.i.d. |
| Sheng et al. 2011 [18] | 40 | English | Rome III | ≥30% improvement in global IBS symptoms | 4 weeks (EoT and 1-month follow-up) | Herbal cone-partitioned and fixed points | Pinaverium bromide 50 mg t.i.d. |
| Chu et al. 2011 [19] | 60 | Chinese | Rome II and TCM criteria | ≥30% improvement in global IBS symptoms | 15 days (EoT) | Syndrome differentiation and treatment | Loperamide 2 mg b.i.d. |
| Chen and Wang 2013 [20] | 64 | Chinese | Rome III | ≥50% improvement in global IBS symptoms | 30 days (EoT) | Fixed points | Trimebutine maleate tablets 100 mg t.i.d. |
| Ma et al. 2013 [21] | 210 | English | Rome III | GSRS total score | 4 weeks (EoT) | Medicamental pulverata-partitioned and fixed points | Pinaverium bromide 50 mg t.i.d. |

IBS-D: diarrhea-predominant IBS; t.i.d.: three times a day; GSRS: gastrointestinal symptom rating scale; EoT: end of treatment; TCM: traditional Chinese medicine.

3.5. Adverse Events. Only one trial reported two cases of mild-to-moderate allergy related to moxibustion, which disappeared after stopping the treatment [21]. The other six trials did not report adverse events.

4. Discussion

IBS is a functional gastrointestinal disorder characterized by chronic or recurrent abdominal pain and/or abdominal discomfort associated with abnormal bowel movement [1]. The diagnosis of IBS is currently based on the presence of characteristic symptoms (abdominal pain/discomfort, bloating/distension, and alterations in defecatory function) and in the absence of organic diseases of the gastrointestinal tract [25, 26]. According to the symptoms, IBS can be divided into different subtypes. Based on the Rome III diagnostic criteria that is currently widely used, IBS is classified into four subtypes including IBS-D, IBS-C (constipation-predominant),...
Random sequence generation (selection bias)
Allocation concealment (selection bias)
Blinding of participants and personnel (performance bias)
Blinding of outcome assessment (detection bias)
Incomplete outcome data (attrition bias)
Selective reporting (reporting bias)

(a) Risk of bias graph: review authors’ judgements about each risk of bias item presented as percentages across all included studies

(b) Risk of bias summary: review authors’ judgements about each risk of bias item for each included study

Figure 2: Risk of bias assessment.
IBS-M (mixed), and IBS-U (unspecified), whereas IBS-D is the most common subtype in China [1, 27, 28]. The pathophysiology of IBS includes abnormal intestinal motility, visceral hypersensitivity, psychosocial distress, neuromodulation disorder in postinfection, and imbalance in motility, visceral hypersensitivity, psychosocial distress, themostcommon subtype in China [1, 27, 28].

Methods of conventional pharmacological medication are influencing researchers to try to find more effective and safer therapies in CAM. Moxibustion is not only a treatment approach of CAM but also an important component of traditional Chinese medicine (TCM). There are several types of moxibustion including scarring moxibustion (burning moxa on the skin), warming moxibustion (burning moxa above the skin), and herb-partition moxibustion (indirect burning interposed by various materials). Warming moxibustion is the most practicable and convenient approach in clinical practice [34]. According to TCM theory, moxibustion warms the interior and dissipates the cold, regulates qi and resolves stasis, softens and dissolves mass, resuscitates yang, and warms and activates the meridians. Previous studies indicate that moxibustion could relieve chronic visceral hyperalgesia (CVH) by activating the spinal dynorphin and orphanin-FQ system [34], decreasing hypothalamic corticotrophin releasing hormone levels [35], and decreasing prokineticin-1 and prokineticin receptor-1 expression [36]. Moxibustion also could enhance the pain threshold and restore sensitivity by decreasing 5-hydroxytryptamine concentration in the colon tissue [37].
Evidence-Based Complementary and Alternative Medicine

Test for overall effect:

\( \tau^2 = 0.06 \)

Heterogeneity:

Test for overall effect:

\( \chi^2 = 0.00; \chi^2 = 1.66, df = 1 (P = 0.69); I^2 = 0\%

Test for subgroup differences:

\( \tau^2 = 0.17 \)

Heterogeneity:

Test for overall effect:

\( \tau^2 = 0.17; \chi^2 = 5.21, df = 1 (P = 0.02); I^2 = 81\%

Test for overall effect:

\( \tau^2 = 0.17; \chi^2 = 1.66, df = 1 (P = 0.69); I^2 = 0\%

Heterogeneity:

Test for overall effect:

\( \tau^2 = 0.09 \)

Heterogeneity:

Test for overall effect:

\( \tau^2 = 1.24 \)

Heterogeneity:

Test for overall effect:

\( \chi^2 = 0.00; \chi^2 = 1.66, df = 1 (P = 0.69); I^2 = 0\%

Test for subgroup differences:

\( \chi^2 = 2.89, df = 1 (P = 0.09), I^2 = 65.4\%

(a) Abdominal pain

(b) Abdominal distension

(c) Abdominal stool

Figure 4: Continued.
patients had a significantly increased expression of 5-HT
herb-partitioned moxibustion. The results showed that IBS-D
5-HT clinical study observed the change in colonic mucosal
5-HT$_3$ among IBS-D patients and assessed the efficacy of
herb-partitioned moxibustion. The results showed that IBS-D
patients had a significantly increased expression of 5-HT$_3$ in
the colonic mucosa, whereas herb-partitioned moxibustion
simultaneously improved IBS-D symptoms and downregu-
lated the level of 5-HT$_3$ [37].

Our meta-analysis showed that moxibustion could
improve global IBS-D patient symptoms and scores, which
was consistent with previous studies [38, 39]. In our meta-
analysis, Jin and Chu et al. [17, 19] reported that moxibustion
could relieve diarrhea and abdominal pain in IBS-D patients,
which was in accordance with the results of Liu and Wu et al.
[37, 40]. However, the improvement of abdominal pain and
abnormal stool was not significantly different in our meta-
analysis with moxibustion treatment, whereas abdominal
distension and defecation frequency improved significantly.
These findings might be associated with different frequencies
of intervention, duration of study, patient age, duration of
run-in period, male-to-female ratio, the number of patients
in the treatment group or control group, or the number of
doctor visits.

Systematic reviews and meta-analyses are often limited by
the quality of the included studies. First, the sample size is
small, in which only 568 patients were included in both mox-
ibustion and pharmacological medication groups. Second,
the treatment mode and the duration were not equivalent;
thus, we could not confirm how long moxibustion treatment
is required to achieve a benefit when treating IBS-D. Third,
because the assessment of improved symptoms of IBS-D was
not the same, it was difficult to accurately assess the effect
of moxibustion. Fourth, because only one study reported the
side effects of moxibustion, we could not assess the overall
side effects during treatment of IBS-D. Fifth, the quality of
the present evidence is limited considering that most of
the included studies were given a high risk of performance
bias for key methodological elements of adequate random
sequence generation and allocation concealment. Finally,
no studies reported an improvement in quality of life for
IBS-D patients, which is correlated with the appearance of
symptoms, protracted time, and severity of the disease [41,
42].

This meta-analysis showed that moxibustion might be
beneficial for IBS-D patients. However, this review had some
limitations. The data are insufficient to recommend the
method as a first-line treatment or to establish the quality of
life and long-term results. Therefore, further research is
required to more accurately assess the results of moxibustion
for treating IBS-D.

### Disclosure

The funder had no role in study design, data collection and
analysis, decision to publish, or preparation of the paper.

### Competing Interests

The authors declare that they have no competing interests.

### Authors’ Contributions

Bozong Tang and Jianliang Zhang contributed equally to this
work.

### Acknowledgments

This work was supported, in part, by the National Natural
Science Foundation of China (81173222) and research subject
in hospital (201509).

| Study or subgroup | Moxibustion | Total | Control | Weight % | Mean difference | Year |
|-------------------|-------------|-------|---------|----------|-----------------|------|
|                    | Mean       | SD    | Mean    | SD       | IV, random, 95% CI |      |
| 3.4.1 Before treatment |            |       |         |          |                 |      |
| Jin 2009          | 1.68       | 0.37  | 39      | 1.69     | 0.43            | 39   |
| Chu et al. 2011   | 3.24       | 1.25  | 30      | 3.46     | 1.32            | 30   |
| Subtotal (95% CI) | 69         | 43.7  | 69      |          |                 |      |
| Heterogeneity: $\chi^2 = 0.00, \chi^2 = 0.37, df = 1 (P = 0.54); I^2 = 0.0%$ |       |       |         |          |                 |      |
| Test for overall effect: $Z = 0.28 (P = 0.78)$ |       |       |         |          |                 |      |
| 3.4.2 After treatment |            |       |         |          |                 |      |
| Jin 2009          | 0.61       | 0.45  | 39      | 0.78     | 0.23            | 39   |
| Chu et al. 2011   | 2.31       | 0.95  | 30      | 2.57     | 0.84            | 20   |
| Subtotal (95% CI) | 69         | 56.3  | 59      |          |                 |      |
| Heterogeneity: $\chi^2 = 0.00, \chi^2 = 0.11, df = 1 (P = 0.74); I^2 = 0%$ |       |       |         |          |                 |      |
| Test for overall effect: $Z = 2.31 (P = 0.02)$ |       |       |         |          |                 |      |
| Total (95% CI)    | 138        | 128   | 100.0   |          | $-0.11 [-0.22, 0.00]$ |      |
| Heterogeneity: $\chi^2 = 0.00, \chi^2 = 2.22, df = 3 (P = 0.53); I^2 = 0%$ |       |       |         |          |                 |      |
| Test for overall effect: $Z = 1.92 (P = 0.05)$ |       |       |         |          |                 |      |
| Test for subgroup differences: $\chi^2 = 1.73, df = 1 (P = 0.19), I^2 = 42.2%$ |       |       |         |          |                 |      |

**Figure 4:** Improvement of specific IBS-D symptoms.
References

[1] L. J. Brandt, W. D. Chey, A. E. Foxx-Orenstein et al., “An evidence-based position statement on the management of irritable bowel syndrome,” *American Journal of Gastroenterology*, vol. 104, supplement I, pp. S1–S35, 2009.

[2] E. Rey and N. J. Talley, “Irritable bowel syndrome: novel views on the epidemiology and potential risk factors,” *Digestive and Liver Disease*, vol. 41, no. 11, pp. 772–780, 2009.

[3] A. P. S. Hungin, L. Chang, G. R. Locke, E. H. Dennis, and V. Barghout, “Irritable bowel syndrome in the United States: prevalence, symptom patterns and impact,” *Alimentary Pharmacology & Therapeutics*, vol. 21, no. 11, pp. 1365–1375, 2005.

[4] D. A. Drossman, C. B. Morris, S. Schneck et al., “International survey of patients with IBS: symptom features and their severity, health status, treatments, and risk taking to achieve clinical benefit,” *Journal of Clinical Gastroenterology*, vol. 43, no. 6, pp. 541–550, 2009.

[5] Y. Ringel, R. E. Williams, L. Kalilani, and S. F. Cook, “Prevalence, characteristics, and impact of bloating symptoms in patients with irritable bowel syndrome,” *Clinical Gastroenterology and Hepatology*, vol. 7, no. 1, pp. 68–72, 2009.

[6] J. M. Inadomi, M. B. Fenney, and D. Bjorkman, “Systematic review: the economic impact of irritable bowel syndrome,” *Alimentary Pharmacology Therapeutics*, vol. 18, no. 7, pp. 671–682, 2003.

[7] L. V. McFarland, “State-of-the-art of irritable bowel syndrome and inflammatory bowel disease research in 2008,” *World Journal of Gastroenterology*, vol. 14, no. 17, pp. 2625–2629, 2008.

[8] R. Carmona-Sánchez and F. A. Tostado-Fernández, “Prevalence of use of alternative and complementary medicine in patients with irritable bowel syndrome, functional dyspepsia and gastroesophageal reflux disease,” *Revista de gastroenterología de México*, vol. 70, no. 4, pp. 393–398, 2005.

[9] S. Magge and A. Lembo, “Complementary and alternative medicine for the irritable bowel syndrome,” *Gastroenterology Clinics of North America*, vol. 40, no. 1, pp. 245–253, 2011.

[10] S. L. Yoon, O. Grundmann, L. Koepp, and L. Farrell, “Management of irritable bowel syndrome (IBS) in adults: conventional and complementary/alternative approaches,” *Alternative Medicine Review*, vol. 16, no. 2, pp. 134–151, 2011.

[11] D. Hu, M. Kang, J. Xiong, and P. Deng, “Irritable bowel syndrome with diarrhea (IBS-D) treated with moxibustion on heat-sensitive acupoints: a randomized controlled trial,” *World Journal of Acupuncture—Moxibustion*, vol. 22, no. 2, pp. 1–5, 2012.

[12] Y. Y. Ni and J. Q. Lu, “Clinical research on moxibustion treatment of diarrhea type irritable bowel syndrome,” *World Journal of Acupuncture-Moxibustion*, vol. 11, no. 3, pp. 19–23, 2001.

[13] J.-W. Park, B.-H. Lee, and H. Lee, “Moxibustion in the management of irritable bowel syndrome: systematic review and meta-analysis,” *BMC Complementary and Alternative Medicine*, vol. 13, article 247, pp. 1–14, 2013.

[14] D. Hu, M. Kang, J. Xiong et al., “Irritable bowel syndrome with diarrhea (IBS-D) treated with moxibustion on heat-sensitive acupoints: a randomized controlled trial,” *World Journal of Acupuncture-Moxibustion*, vol. 22, no. 2, pp. 1–5, 2012.

[15] S. J. Luo, J. H. Long, and L. Huang, “The curative effect observation and nursing of moxibustion combined with pinaverium bromide tablets to cure abdominal pain and diarrhea intestine irritable syndrome,” *Journal of Jingshangan Medical College*, vol. 15, no. 4, pp. 39–40, 2008.

[16] Y. B. Zhang, C. Y. Yan, and S. Xie, “Thirty cases of diarrhea-predominant irritable bowel syndrome treated by ginger-partitioned moxibustion,” *Jiangxi Journal of Traditional Chinese Medicine*, vol. 38, no. 296, pp. 69–70, 2007.

[17] G. D. Jin, “The efficiency observation of tianjju therapy on irritable bowel syndrome of diarrhea type,” *Journal of Zhejiang College of Traditional Chinese Medicine*, vol. 33, no. 3, pp. 415–416, 2009.

[18] C. Sheng, D. Dongqing, Y. Ma, Z. Wang, S. Gao, and X. Wang, “clinical study on herbal cone-partitioned moxibustion for irritable bowel syndrome due to spleen-qi deficiency,” *Journal of Acupuncture and Tuina Science*, vol. 9, no. 5, pp. 265–268, 2011.

[19] H. Chu, X. Huang, X. Li, H. Chen, and Y. Ding, “Moxibustion for diarrhea-type irritable bowel syndrome: a clinical study,” *Journal of Anhui TCM College*, vol. 30, no. 6, pp. 33–36, 2011.

[20] S. X. Chen and Y. W. Wang, “Thirty two cases of diarrhea-predominant irritable bowel syndrome treated by heat-sensitive moxibustion,” *Zhejiang Journal of Traditional Chinese Medicine*, vol. 48, no. 3, pp. 199–120, 2013.

[21] Y.-X. Ma, X. Liu, C.-Z. Liu et al., “Randomized clinical trial: the clinical effects of herb-partitioned moxibustion in patients with diarrhoea-predominant irritable bowel syndrome,” *Evidence-Based Complementary and Alternative Medicine*, vol. 2013, Article ID 605460, 8 pages, 2013.

[22] J. P. T Higgins and S. Green, Eds., *Cochrane Handbook for Systematic Reviews of Interventions*, Version 5.1.0, The Cochrane Collaboration, 2011, http://handbook.cochrane.org.

[23] J. Luo and W. D. Leng, Eds., *Theory & Practice of Systematic Review/Meta-Analysis*, Military Medical Science Press, Beijing, China, 2013.

[24] J. P. T Higgins and S. G. Thompson, “Quantifying heterogeneity in a meta-analysis,” *Statistics in Medicine*, vol. 21, no. 11, pp. 1539–1558, 2002.

[25] B. D. Cash and W. D. Chey, “Diagnosis of irritable bowel syndrome,” *Gastroenterology Clinics of North America*, vol. 34, no. 2, pp. 205–220, 2005.

[26] D. A. Drossman and D. L. Dumitrascu, “Rome III: new standard for functional gastrointestinal disorders,” *Journal of Gastrointestinal and Liver Diseases*, vol. 15, no. 3, pp. 237–241, 2006.

[27] S. Q. Zhou and D. G. Li, “"The epidemic survey of Fujian teenagers with irritable bowel syndrome," *Chinese Journal of Digestive Diseases*, vol. 27, no. 3, pp. 169–173, 2007 (Chinese).

[28] G. F. Longstreth, W. G. Thompson, W. D. Chey, L. A. Houghton, F. Mearin, and R. C. Spiller, “Functional bowel disorders,” *Gastroenterology*, vol. 130, no. 5, pp. 1480–1491, 2006.

[29] A. W. Bundeff and C. B. Woodis, “Selective serotonin reuptake inhibitors for the treatment of irritable bowel syndrome,” *Annals of Pharmacotherapy*, vol. 48, no. 6, pp. 777–784, 2014.

[30] S. Zakko, G. Barton, E. Weber, C. Dunger-Baldau, and A. Rühl, “Randomised clinical trial: the clinical effects of a novel neurokinin receptor antagonist, DNK333, in women with diarrhoea-predominant irritable bowel syndrome,” *Alimentary Pharmacology and Therapeutics*, vol. 33, no. 12, pp. 1311–1321, 2011.

[31] M. Ortiz-Lucas, A. Tobías, P. Saz, and J. J. Sebastián, “Effect of probiotic species on irritable bowel syndrome symptoms: a bring up to date meta-analysis,” *Revista Espanola de Enfermedades Digestivas*, vol. 105, no. 1, pp. 19–36, 2013.
10 Evidence-Based Complementary and Alternative Medicine

[32] A. Rezaie, S. Nikfar, and M. Abdollahi, “The place of antibiotics in management of irritable bowel syndrome: a systematic review and meta-analysis,” Archives of Medical Science, vol. 6, no. 1, pp. 49–55, 2010.

[33] S. D. Dorn, T. J. Kaptchuk, J. B. Park et al., “A meta-analysis of the placebo response in complementary and alternative medicine trials of irritable bowel syndrome,” Neurogastroenterology and Motility, vol. 19, no. 8, pp. 630–637, 2007.

[34] L. Qi, H.-R. Liu, T. Yi et al., “Warming moxibustion relieves chronic visceral hyperalgesia in rats: relations to spinal dynorphin and orphanin-FQ system,” Evidence-Based Complementary and Alternative Medicine, vol. 2013, Article ID 920675, 10 pages, 2013.

[35] E.-H. Zhou, X.-M. Wang, G.-H. Ding et al., “Suspended moxibustion relieves chronic visceral hyperalgesia and decreases hypothalamic corticotropin-releasing hormone levels,” World Journal of Gastroenterology, vol. 17, no. 5, pp. 662–665, 2011.

[36] L. Y. Wu, C. H. Bao, L. B. Ge et al., “Mild moxibustion at tianshu (ST 25) decreases expression of prokineticin-1 and prokineticin receptor-1 in colon tissue of rats with chronic visceral hyperalgesia,” Neural Regeneration Research, vol. 6, no. 33, pp. 2600–2604, 2011.

[37] H. R. Liu, X. G. Hua, Y. Yang, and H. G. Wu, “Clinical study on 5-HT expression in colonic mucosa and the treatment of herb-partition moxibustion in diarrhea-predominant IBS,” Liaoning Zhongyi Zazhi, vol. 33, no. 8, pp. 984–985, 2006.

[38] Y. A. Saito, P. Schoenfeld, and G. R. Locke III, “The epidemiology of irritable bowel syndrome in North America: a systematic review,” The American Journal of Gastroenterology, vol. 97, no. 8, pp. 1910–1915, 2002.

[39] J.-W. Park, B.-H. Lee, and H. Lee, “Moxibustion in the management of irritable bowel syndrome: systematic review and meta-analysis,” BMC Complementary and Alternative Medicine, vol. 13, article 247, 14 pages, 2013.

[40] H. G. Wu, C. Zhao, Z. Shi, H. P. Chen, Y. Liu, and S. M. Liu, “Clinical study on spleen-stomach-reinforcing moxibustion treatment of diarrhea-type irritable bowel syndrome,” World Journal of Acupunct-Moxibust, vol. 12, no. 1, pp. 10–15, 2002.

[41] A. Wilson, G. F. Longstreth, K. Knight et al., “Quality of life in managed care patients with irritable bowel syndrome,” Managed Care Interface, vol. 17, no. 2, pp. 24–34, 2004.

[42] J. M. Park, M.-G. Choi, Y. S. Kim et al., “Quality of life of patients with irritable bowel syndrome in Korea,” Quality of Life Research, vol. 18, no. 4, pp. 435–446, 2009.